Kezar Life Sciences (KZR)

Company Profile

Based in South San Francisco, Kezar Life Sciences is combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function and inhibit multiple drivers of disease via a single target. KZR-616, a first-in-class selective immunoproteasome inhibitor, is being evaluated in severe and underserved autoimmune diseases. Additionally, KZR-261, the first clinical candidate for the treatment of cancer from the company's protein secretion program targeting the Sec61 translocon, is undergoing IND-enabling activities.

Company profile

Ticker

KZR

Exchange

NASDAQ

Website

kezarlifesciences.com

CEO

John Fowler

Incorporated

Delaware

Location

California

Fiscal year end

Dec 31

Sector

Professional, Scientific, and Technical Services > Research and Development in Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Bausch Health Companies ...

SEC CIK

0001645666

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

KZR stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

POS AM

Prospectus update (post-effective amendment)

14 Mar 23

Kezar Life Sciences Reports Fourth Quarter and Year End 2022 Financial Results and Provides Business Update

14 Mar 23

POSASR

Automatic shelf registration (post-effective amendment)

14 Mar 23

8-K

Departure of Directors or Certain Officers

28 Feb 23

8-K

Results of Operations and Financial Condition

10 Nov 22

Kezar Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update

11 Aug 22

Transcripts

KZR

Earnings call transcript

2020 Q2

9 Aug 20

Latest ownership filings

View all

Avidity Partners Management LP

SUVRETTA CAPITAL MANAGEMENT, LLC

13 Feb 23

Change in insider ownership

7 Feb 23

Change in insider ownership

Change in insider ownership

1 Feb 23

SC 13G/A

FRANKLIN RESOURCES INC

31 Jan 23

Financial summary

Financial statements Chart KZR financial data

Quarter (USD)	Dec 22	Sep 22	Jun 22	Mar 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	40.46 mm	40.46 mm	40.46 mm	40.46 mm	40.46 mm	40.46 mm
Cash burn (monthly)	8.00 mm	1.87 mm	6.68 mm	5.93 mm	5.29 mm	4.90 mm
Cash used (since last report)	22.24 mm	5.20 mm	18.57 mm	16.49 mm	14.72 mm	13.63 mm
Cash remaining	18.22 mm	35.26 mm	21.89 mm	23.97 mm	25.74 mm	26.82 mm
Runway (months of cash)	2.3	18.9	3.3	4.0	4.9	5.5

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2022

KZR institutional ownership history Ownership history

97.3% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	122	130	-6.2%
Opened positions	11	25	-56.0%
Closed positions	19	23	-17.4%
Increased positions	53	57	-7.0%
Reduced positions	41	31	+32.3%

13F shares	Current	Prev Q	Change
Total value	382.09 bn	578.78 mm	+65915.5%
Total shares	66.50 mm	65.05 mm	+2.2%
Total puts	900.00	23.40 k	-96.2%
Total calls	183.70 k	524.70 k	-65.0%
Total put/call ratio	0.0	0.0	-89.0%

Largest owners	Shares	Value	Change
Avidity Partners Management	6.78 mm	$47.75 bn	+25.3%
Morningside Venture Investments	6.25 mm	$32.65 mm	0.0%
Orbimed Advisors	4.58 mm	$32.27 bn	+158.8%
STT State Street	4.25 mm	$29.95 bn	NEW
BLK Blackrock	4.23 mm	$29.79 bn	+3.1%
Suvretta Capital Management	3.50 mm	$24.67 bn	+7.0%
BLVGF Bellevue	3.03 mm	$21.34 bn	0.0%
Vanguard	3.03 mm	$21.30 bn	+1.1%
BBBOF BB Biotech	3.00 mm	$0.00	-39.0%
Millennium Management	2.90 mm	$20.35 bn	-2.2%

Largest transactions	Shares	Bought/sold	Change
STT State Street	4.25 mm	+4.25 mm	NEW
Orbimed Advisors	4.58 mm	+2.81 mm	+158.8%
Victory Capital Management	0.00	-2.36 mm	EXIT
BBBOF BB Biotech	3.00 mm	-1.92 mm	-39.0%
HealthCor Management	0.00	-1.61 mm	EXIT
Deerfield Management	1.43 mm	+1.43 mm	NEW
Avidity Partners Management	6.78 mm	+1.37 mm	+25.3%
Logos Global Management	0.00	-950.00 k	EXIT
Marshall Wace	12.75 k	-645.69 k	-98.1%
Woodline Partners	0.00	-580.18 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

KZR insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
6 Feb 23	Morningside Venture Investments	Common Stock	Sell	Dispose S	No	No	6.883	40,000	275.32 k	5,447,993
3 Feb 23	Morningside Venture Investments	Common Stock	Sell	Dispose S	No	No	7.146	25,000	178.65 k	5,487,993
2 Feb 23	Morningside Venture Investments	Common Stock	Sell	Dispose S	No	No	7.19	50,000	359.50 k	5,512,993
1 Feb 23	Morningside Venture Investments	Common Stock	Sell	Dispose S	No	No	6.95	40,000	278.00 k	5,562,993
31 Jan 23	Morningside Venture Investments	Common Stock	Sell	Dispose S	No	No	7.08	30,000	212.40 k	5,602,993
30 Jan 23	Morningside Venture Investments	Common Stock	Sell	Dispose S	No	No	6.91	30,000	207.30 k	5,632,993
25 Jan 23	Morningside Venture Investments	Common Stock	Sell	Dispose S	No	No	6.85	50,000	342.50 k	5,662,993
24 Jan 23	Morningside Venture Investments	Common Stock	Sell	Dispose S	No	No	6.98	80,000	558.40 k	5,712,993
23 Jan 23	Morningside Venture Investments	Common Stock	Sell	Dispose S	No	No	6.81	80,000	544.80 k	5,792,993